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Abstract
Background: Osteogenesis imperfecta (OI) is a heritable disease marked by a varying degree of low bone
mass and increased incidence of fractures. Approximately 1 in 15 000 and 1 in 20 000 children are affected by
this connective tissue disorder. Although, the mainstay of treatment for children and adolescents with OI is
multidisciplinary, the role of bisphosphonates is rapidly becoming the standard of care. Bisphosphonates work
by inhibiting osteoclast mediated bone resorption, therefore, allowing osteoblast more time for bone
formation. Currently, very little is known about the effect of oral bisphosphonate treatment; despite it being
under investigation in controlled trials. This can be attributed to the lack of blinding and relatively small study
populations in previous reviewed studies. Therefore, the purpose of this systematic review is to determine the
efficacy of bisphosphonates in increasing bone mineral density and decreasing the incidence of fractures in a
larger study population with adequate blinding in randomized control trials.
Methods: An exhaustive literature search was performed in the following databases Medline-Ovid,
CINAHL,Web of Science, and Medline-PubMed. The keywords include “osteogenesis imperfecta,” “children,”
and “bisphosphonates.” Articles selected were limited to those studies in the English language, studies with a
publication date in or after 2010, randomized control trials and a study population greater than 100
participants.
Results: Two articles met inclusion criteria. The first study included was a randomized, double-blind,
placebo-controlled study with 143 participants who demonstrated that risendronate was effective in both
decreasing the incidence of fractures and increasing bone mineral density. The second study was a prospective,
randomized, double-blind, parallel- group,placebo- controlled study with 139 participants. This study
concluded that alendronate increased bone mineral density but did not decrease the incidence of fractures.
Conclusion: Largely, this conflict in opinion is the reason bisphosphonates are in great debate for the
treatment of OI. It is essential to come to a consensus on whether or not bisphosphonates remain an adequate
and safe treatment option for children with OI. The evidence presented in this paper proves that
bisphosphonates are useful in increasing BMD, but the evidence on decreasing incidence of fractures remains
inconclusive, indicating further research is necessary.
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Abstract 
 
Background: Osteogenesis imperfecta (OI) is a heritable disease marked by a varying 
degree of low bone mass and increased incidence of fractures. Approximately 1 in 15 000 
and 1 in 20 000 children are affected by this connective tissue disorder. Although, the 
mainstay of treatment for children and adolescents with OI is multidisciplinary, the role 
of bisphosphonates is rapidly becoming the standard of care. Bisphosphonates work by 
inhibiting osteoclast mediated bone resorption, therefore, allowing osteoblast more time 
for bone formation. Currently, very little is known about the effect of oral bisphosphonate 
treatment; despite it being under investigation in controlled trials. This can be attributed 
to the lack of blinding and relatively small study populations in previous reviewed 
studies. Therefore, the purpose of this systematic review is to determine the efficacy of 
bisphosphonates in increasing bone mineral density and decreasing the incidence of 
fractures in a larger study population with adequate blinding in randomized control trials.   
 
Methods: An exhaustive literature search was performed in the following databases 
Medline-Ovid, CINAHL,Web of  Science, and Medline-PubMed. The keywords include 
“osteogenesis imperfecta,” “children,” and “bisphosphonates.” Articles selected were 
limited to those studies in the English language, studies with a publication date in or after 
2010, randomized control trials and a study population greater than 100 participants. 
 
Results: Two articles met inclusion criteria. The first study included was a randomized, 
double-blind, placebo-controlled study with 143 participants who demonstrated that 
risendronate was effective in both decreasing the incidence of fractures and increasing 
bone mineral density. The second study was a prospective, randomized, double-blind, 
parallel- group,placebo- controlled study with 139 participants. This study concluded that 
alendronate increased bone mineral density but did not decrease the incidence of 
fractures. 
 
Conclusion:  Largely, this conflict in opinion is the reason bisphosphonates are in great 
debate for the treatment of OI. It is essential to come to a consensus on whether or not 
bisphosphonates remain an adequate and safe treatment option for children with OI. The 
evidence presented in this paper proves that bisphosphonates are useful in increasing 
BMD, but the evidence on decreasing incidence of fractures remains inconclusive, 
indicating further research is necessary.  
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The Use of Bisphosphonates in Increasing Bone Mineral Density and Decreasing Fracture Occurrence in Children with Osteogenesis Imperfecta 
BACKGROUND 
 Osteogenesis imperfecta (OI) is a rare heritable disease of connective tissue 
affecting between 1 in 15 000 and 1 in 20 000.1 Characteristics of OI include a varying 
degree in low bone mass and increased susceptibility of fractures.  Additionally, patients 
with OI may experience muscle weakness, hearing loss, fatigue, joint laxity, scoliosis, 
blue sclera, dentinogenesis imperfecta or brittle teeth, short stature and even restrictive 
pulmonary disease.2 Some patients have considerable skeletal deformity with normal 
sclera and others have little deformity and very blue sclera. A small portion of patients 
will not survive infancy.3  
 The majority of cases of OI are a result of disturbances in the formation of type 1 
collagen. Type 1 collagen fibers play a large role in the ductility and toughness of bone. 
Most cases of OI are inherited as autosomal dominant and are a result of a mutation in a 
gene that encodes for type 1 collagen. The majority of those with OI, around 90% in fact, 
have a mutation in either COL1A1 or COL1A2.2 
 A review conducted in 1979 was performed to distinguish genetic heterogeneity 
of OI and to determine the relationship between surviving and lethal cases. This review 
performed by Sillence et al2 was conducted in Victoria, Australia. The authors confirmed 
that there are at least four types of OI. Type I was found to be autosomal dominant and 
relativity mild. This is the most common form of OI, it comprises about 50% of the 
population with OI.2 It consists of normal or slightly short stature, little to no bone 
deformity, blue sclera, ligament laxity, hearing loss and dentinogenesis imperfecta. Type 
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II, autosomal recessive in inheritance is the most lethal form of OI. Pronounced 
deformities, multiple fractures at birth and underdeveloped skull attribute to the lethality 
of this type. Type III also autosomal recessive is severe in nature. It is associated with 
fractures at birth, short stature, severe scoliosis, triangular facies, grey sclera and 
dentinogenesis imperfecta. Lastly, type IV is autosomal dominant and is moderately 
severe. Short stature, scoliosis, white or grey sclera and dentinogenesis imperfecta are 
associated with this type. The Sillence classification has been expanded to encompass 
type V and type VI. These two types are not associated with type 1 collagen, but are 
treated similarly as the other types.1-3 This classification is accepted and widely used 
today in the diagnosis of OI. 
 The mainstay of treatment for children and adolescents with OI is 
multidisciplinary involving physiotherapy, rehabilitation and orthopedic surgery.  It is of 
no surprise that bisphosphonates are rapidly becoming a standard of care.4 For more than 
three decades, bisphosphonates have been used for multiple skeletal disorders.5 
Bisphosphonates can offer clinical benefit in conditions with imbalances between 
osteoblast-mediated bone formation and osteoclasts-mediated bone resorption.5 
Bisphosphonates have a high affinity for bone mineral because they bind to 
hydroxyapatite crystals. Therefore, bisphosphonates skeletal retention is dependent on the 
availability of hydroxyapatite binding sites. Bisphosphonates are incorporated into these 
sites during active bone remodeling, which occurs in conditions leading to accelerated 
bone turnover. Also, by inhibiting osteoclast mediated bone resorption, bisphosphonates 
allow bone-forming osteoblast more time for bone formation. Although, bisphosphonate 
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therapy is well established for children with OI, data is limited in terms of efficacy and 
risk of harm.5 
 Currently very little is known about the effect of oral bisphosphonate treatment, 
despite it being under investigation in controlled trials.6 A systematic review7 conducted 
in 2009 on nine studies, revealed multiple limitations in determining the efficacy of 
bisphosphonates when related to incidence of fractures and increasing bone mineral 
density. A major limitation discussed in the review, was focused on the small sample size 
of each study. As stated in the review the largest sample size was 64 participants. 
Another limitation noted in the review was that five of the nine studies were not blinded.7 
The purpose of this systematic review is to analyze data that had been established after 
2009, with larger study populations and blinding.  
METHODS 
An exhaustive literature search was performed in the following databases 
Medline-Ovid, CINAHL, Web of science, and Medline-PubMed. The keywords utilized 
to perform the search include “osteogenesis imperfecta,” “children,” and 
“bisphosphonates.” Selection of articles was based on an inclusion and exclusion criteria.. 
Articles selected were limited to those studies in the English language, studies with a 
publication date in or after 2010, randomized control trials and a study population greater 
than 100 participants. Grading of Recommendations, Assessment, Development and 
Evaluations (GRADE) was used to assess the quality of each of the articles reviewed.8  
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RESULTS 
Initially, a comprehensive search yielded a total of 71 articles. After careful 
review a total of two articles 9,10 met the inclusion and exclusion criteria. Both articles 
selected were randomized control trials, conducted in or after 2010, with a study 
population of greater than 100 participants. See Table I. 
 Bishop et al9 conducted an international, randomized, double blind, placebo- 
controlled study to determine if the use of risendronate, a bisphosphonate, was an 
effective treatment for children with OI. A total of 147 patients were enrolled at 20 
hospital centers across 13 countries. Patients were stratified into two groups based on 
age, one group with an age range of 4-9 and the other 10-15 years old. The groups were 
then randomly assigned to either receive treatment or placebo by a telephone based 
interactive voice response system in a 2:1 ratio. The risendronate and placebo tablets 
were identical in appearance. The study investigators, patients and the center personnel 
were all blinded during the first 12 months. After 12 months all patients received the 
study medication in an open label phase. The open label phase was conducted for an 
additional two years.9 
The inclusion criteria consisted of children with OI from the ages of 4-15 years. 
Eligibility was based on a history of at least one non-traumatic or low impact fracture and 
an age-adjusted and sex-adjusted areal bone mineral density (BMD) Z score of -1.0 or 
less. Patients were excluded if they weighed less than 10 kg, had a history of cancer 
within the last five years, had untreated rickets during the previous year, had a serum 25-
hydroxyvitamin D concentration of less than 20 nmol/L, had previous treatment that 
could affect the results of the study or had disease severe enough to warrant the use of 
intravenous bisphosphonates.9  
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The patients were dosed according to weight. Patients who weighed 10-30kg 
received 2.5mg risendronate or placebo daily. Those who weighed more than 30kg 
received 5mg of risendronate or placebo daily. The demographics and disease 
characteristics were similar between the two groups. The lumbar spine BMD between the 
two groups was also similar, but differed in their total body BMD. The risendronate 
group had a total body BMD Z score of -1.42 and the placebo group total body BMD Z 
score of -1.82.9 
The primary endpoint was the percentage change from baseline in lumbar spine 
areal BMD after 12 months. This outcome was assessed using dual-energy x-ray 
absorptiometry of the lumbar spine and total body at months 6, 12, 24 and 36. The 
secondary endpoint consisted of multiple outcomes, such as the incidence and rate of new 
vertebral and non-vertebral fractures, as well as percentage change from baseline in bone 
turnover markers. Although multiple outcomes were assessed as a secondary endpoint, of 
interest in this review is the incidence of new non-vertebral fractures. New non-vertebral 
fractures were confirmed based on symptoms and radiograph findings.9 
After randomization was complete, 94 patients were assigned to the risendronate 
group and 49 patients were assigned to the placebo group. The mean percentage increase 
in spine BMD after one year was 16.3% (95% CI 14.4-18.2) in the risendronate group 
and 7.6% (95% CI 5.1-10.1) in the placebo group. A p value of <0.0001 was calculated. 
After the first year, when both groups received the risendronate, increases of lumbar 
spine BMD were similar in the two groups. In the placebo-control phase, non- vertebral 
fractures were confirmed in 29 (31%) of the 94 participants in the treatment group and 24 
(49%) of the 49 participants in the placebo group. A calculated p value of 0.0446 was 
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noted. The relative risk ratio of 0 .63, which resulted in a 39% reduction of fractures, was 
determined and the number needed to treat was 6. After 12 months, risendronate was 
found to reduce the risk of recurrent fractures by 42% (HR 0.58, 95% CI 0 .4-1.0) with a 
calculated p value of 0.0416.9 
The authors determined that oral risendronate increased BMD and reduced the 
risk of recurrent fractures. In addition, the authors recommend the use of risendronate as 
a valid treatment option for children with osteogenesis imperfecta.9 
Ward et al10 conducted a prospective, randomized, double-blind, parallel-group, 
placebo-controlled, multicenter study. The study focused on the efficacy and safety of 
daily oral alendronate in children with osteogenesis imperfecta. Children and adolescents 
with OI were recruited at 16 Shriners hospitals in North America. Patients were 
randomized in a 3:1 ratio to alendronate and placebo groups. They were then stratified 
according to weight. Those that were 40kg or less received 5mg daily of alendronate. 
Individuals greater than 40kg received 10mg of alendronate. The placebo was identical in 
appearance despite the differences in dosage.10 
The inclusion criteria included children, both males and females, ages 4-18 years 
old. Patients were required to have had a diagnosis of type III or IV OI. If patients were 
diagnosed with type I, they must have had one or more of the following associated 
symptoms: chronic pain, more than three fractures per year, minimal trauma for the 
previous 2 years, or a limb deformity requiring surgery. Patients were excluded if they 
were unable to comply fully with the dosing instructions, had previously received 
treatment with a bisphosphonate, or were regularly using drugs that altered gastric 
acidity.10  
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Baseline characteristics between the two groups were similar. Lumbar spine BMD 
z score was -4.50 ± 1.45 in the alendronate group and -4.56 ± 1.61 in the placebo group. 
The number of lifetime fractures across the two groups was 51.6 ± 70.8 in the treatment 
group and 40.6 ± 53.6. Also, similar between groups was the number of fractures 
reported during the year before the study. There were 2.0 ± 3.0 in the alendronate group 
and 2.6 ± 2.6 in the placebo group.10 
The primary endpoint of this study was the change in lumbar spine areal BMD z- 
score. To assess this, dual- energy x-ray absorptiometry was performed at baseline and at 
6 months intervals. The scans were then analyzed at a central facility. The results were 
converted to age and sex- specific z scores using data provided by the manufacturer. The 
secondary endpoints were cortical width at the midpoint of the second metacarpal as 
determined by radiographs, the number of radiologically confirmed fractures, the number 
of investigator-reported fractures and the change in cortical width of the iliac bone 
determined by transiliac biopsy. The focus of this review is aimed at the number of 
fractures during the course of this two year study. This endpoint was assessed in two 
ways. The first method was performed by obtaining radiographs of the upper extremity 
long bones and lower extremity long bones at baseline and at yearly intervals. The 
radiographs were assessed for evidence of fractures by three blinded radiologist. The 
determination of present fractures must have been unanimous. Fractures determined in 
this manner were titled radiologically confirmed fractures. The second method was 
reported by the parent or guardian of the patients. The fractures were not necessarily 
confirmed by radiographs, but were recorded at each study visit by the investigator. 
Fractures identified in this manner were titled investigator-reported fractures.10 
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A total of 139 patients with OI were randomized. Twenty six patients in the 
alendronate group and four patients in the placebo group discontinued. Discontinuation 
was due to loss to follow-up, adverse events, withdrawn consent and protocol deviation. 
After factoring out the patients that discontinued the study, 83 patients in the alendronate 
group and 26 patients in the placebo group completed the two year study. At the 
completion of the study lumbar spine areal BMD was significantly increased in both 
alendronate and placebo groups. In the alendronate group, BMD increased by 51% and 
12% in the placebo group. The lumbar spine BMD Z score in the treatment group 
increased from -4.6 to -3.3, a p value of <0.001, revealing a significant improvement. On 
the other hand, the z scores in the placebo group went from -4.5 to -4.6, a rather 
insignificant increase. When assessing the incidence of fractures that were radiologically 
confirmed by month 24, there was little difference between the two groups. In the 
alendronate group there was 1.96 with a 95% CI of 1.40-2.75. In the placebo group the 
incidence of fractures was 1.75 with a 95% CI of 1.10-2.80, a calculated p value of 
0.614.10 
According to the authors, they found that oral alendronate over a course of 24 
months was effective in increasing lumbar spine areal BMD z score over placebo. They 
also concluded, there was no significant effect of alendronate on the incidence of 
fractures.10 
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DISCUSSION 
 Objectives of this systematic review include the efficacy of bisphosphonates for 
increasing bone mineral density and decreasing incidence of fractures. Although 
bisphosphonates have been studied extensively, it is evident that the true efficacy and 
long term effects are not well known, especially when it comes to children suffering with 
OI. Adverse effects of bisphosphonates are not to be taken lightly; osteonecrosis of the 
jaw, hypocalcemia, oversuppression of bone turnover and atrial fibrillation are all serious 
side effects.5 Thus, it is imperative to weigh both the risks and benefits when using this 
treatment in a population as delicate as children. 
 Bishop et al9 concluded that oral risendronate increased bone mineral density and 
decreased the incidence of fractures. In terms of blinding and randomization this study 
has proven to be well done, but it is not without limitations. One limitation that 
jeopardizes its validity significantly is the inconsistency between the control and 
treatment groups. In other words, the prognostic variables at baseline were not similar. To 
restate the facts, the treatment group baseline total body bone mineral density z- score 
was -1.42 and in the placebo group it was -1.82. This is a significant difference and 
affects the validity of the study to a great degree. It is undoubtedly so, the treatment 
group had an overall better result when compared to the placebo group since it had a 
much better prognosis at baseline. Despite the differences in total body BMD at baseline, 
groups were otherwise prognostically balanced. For instance, when considering lumbar 
spine BMD, groups were nearly identical; with a z score of -2.130 in the treatment group 
and -2.120 in the placebo group.   
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In comparison, the study performed by Ward et al10 lumbar spine BMD was also 
similar between the two groups at baseline. This study did not analyze total body BMD, 
therefore, it is difficult to determine if the two groups were more prognostically balanced 
at baseline than in the study conducted by Bishop et al.9 
Of importance, Ward et al10 concluded that alendronate increased lumbar spine 
BMD but was not associated with decreased fracture outcomes. Both studies agreed that 
bisphosphonates increase BMD, but differ when it comes to incidence of fractures. This 
could be for many reasons. One reason could be that both studies were different in terms 
of length. Bishop et al9 was one year and Ward et al10 was two years. It is possible within 
the first year of treatment, incidence of fractures improve but later plateau yielding little 
to no effect. Another reason can be attributed to the difference in the type of 
bisphosphonate. Bishop et al9 used the treatment drug oral risendronate and Ward et al10 
used oral alendronate. Both study medications are third generation bisphosphonates,5 it is 
possible that a slight alteration in chemical structure could lead to a difference in 
treatment effect. The last possibility for differences in results could be attributed to the 
severity of the disease. Ward et al10 had an overall study population with a greater 
amount of participants with OI type III and IV, the more severe of the phenotypes. To be 
exact, Ward et al10 had a total number of participants with Type III OI of 39 in both 
treatment and placebo groups combined. Whereas, Bishop et al9 had five study 
participants with Type III in both treatment and placebo groups combined. This is a 
significant difference in the severity of disease across both studies. With the numerous 
differences accounted for across both studies, it is evident why, in fact, both studies 
concluded in a difference in opinion.  
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CONCLUSION 
Largely, this conflict in opinion is the reason bisphosphonates are in great debate 
for the treatment of OI. As medical providers and researchers it is essential to come to a 
consensus on whether or not bisphosphonates remain an adequate and safe treatment 
option for children with OI. The evidence presented in this paper proved that 
bisphosphonates are useful in increasing BMD, but the evidence on decreasing incidence 
of fractures remains inconclusive.  
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TABLE 1 GRADE profile: Bisphosphonate use in increasing BMD and decreasing reoccurrence of fractures in children with OI. 
  
 
a: In the Bishop et al9 study, groups differed in mean total body BMD at baseline. The treatment group had a baseline total body BMD Z score of -1.42 and -1.82 in the 
placebo group. Groups otherwise had a similar prognosis at baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality Assessment Summary of Findings 
Importance  Downgrade Criteria  Number of Patients Effect 
Quality No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely Study 
Treatment 
(total) 
Placebo or 
no treatment 
(total) 
Results 
 
Increasing bone mineral density 
Mean Z- 
score at 
baseline 
Mean Z- 
score at 
study 
completion 
 
2 
 
2 RCTs 
 
 No 
serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
Serious 
inconsistenciesa 
No bias 
likely 
Bishop et al9 94 49 
Treatment group    
 
Moderate Critical 
   -2.130 -1.703 
Placebo group 
   -2.120 -2.128 
Ward et al10 109 30 
Treatment group 
-4.500 
 -3.280 
Placebo group 
 
-4.560 -4.420 
Decreasing incidence of fractures 
Relative 
Risk 
Ratio 
Number 
Needed to 
Treat 
 
2 2 RCTs  
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
Serious 
inconsistenciesa 
No bias 
likely 
Bishop et al9 94 49 0.63 NNT 6 
Moderate Critical 
Ward et al10 109 30 1.12 NNT 476 
